Neumora Therapeutics (NMRA) Other Operating Expenses (2023 - 2025)
Neumora Therapeutics (NMRA) posted quarterly Other Operating Expenses of $5.0 million for Q3 2025, down 92.18% quarter-over-quarter from $63.9 million in Q4 2023.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Other Operating Expenses (2023 - 2025) Analysis & Trends
Neumora Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $5.0 million for Q3 2025.
- In Q3 2025, Other Operating Expenses changed N/A year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (changed N/A YoY), while the FY2025 annual figure was $5.0 million, changed N/A from the prior year.
- Other Operating Expenses for Q3 2025 stood at $5.0 million, down from $63.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $63.9 million in Q4 2023, with the low at $5.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Neumora Therapeutics | 245.34 Mn | 245.34 Mn | - |